Budget Impact Analysis of Single-Inhaler Triple Therapy (SITT) of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate for Moderate to Very Severe Patients With COPD in Argentina
Author(s)
Francisco Pinto, MSc1, Ariel Blua, PhD2, Martin Sivori, PhD3, Daniel Pascansky, PhD3.
1Health Economist [Access], AstraZeneca, Santiago, Chile, 2Respiratory & Immunology Lead [BioPharmaceuticals Medical], AstraZeneca, Buenos Aires, Argentina, 3Hospital Ramos Mejía, Buenos Aires, Argentina.
1Health Economist [Access], AstraZeneca, Santiago, Chile, 2Respiratory & Immunology Lead [BioPharmaceuticals Medical], AstraZeneca, Buenos Aires, Argentina, 3Hospital Ramos Mejía, Buenos Aires, Argentina.
OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is a common and debilitating chronic disease characterized by airflow limitation and chronic respiratory symptoms such as dyspnea, cough, and sputum production, among other symptoms. In Argentina, it has been estimated that more than 2.3 million Argentineans have COPD, which represents a significant healthcare burden associated with cardiopulmonary (lung and/or heart) events affecting disease course and quality of life. This research aimed to assess the impact of introducing a SITT of budesonide (ICS), glycopyrronium (LAMA), and formoterol fumarate (LABA) for patients with moderate to very severe COPD in Argentina
METHODS: A budget impact model (BIM) was developed and populated from the perspective of Argentinean payers over a three-year time horizon. Eligible patients were over 40 years old (INDEC 2023). Epidemiology assumptions such as prevalence (14.5%), moderate to severe COPD (61%) and patient eligibility for triple therapy were obtained from a local study and validated by medical experts. Around 213,510 patients were estimated and included in the BIM. The acquisition cost of therapies was obtained from public data sources (Kairos). Moderate and severe exacerbation costs were estimated based on previous published work in Argentina. All costs were expressed in USD on 15 Jun 2023 (1 USD = 258 ARG). This base case assumes that adopting multiple inhaler triple therapies (MITTs) is reduced and moved from 50%/40%/35% to 40%/30%/25% in terms of usage over three-year horizon
RESULTS: Over three years, adopting SITT generated savings accumulating to US$10.78m. Savings were primarily driven by lower treatment acquisition costs vs. MITT (US$9.1). Rescue therapies and moderate exacerbation savings were USD 0.4 m and USD 1.1 m, respectively
CONCLUSIONS: Single Inhaler Triple Therapy (SITT: ICS/LAMA/LABA) offers cost-savings to a healthcare budget when replacing multiple inhaler triple therapies (MITTs) in Argentina for patients with moderate to very severe COPD
METHODS: A budget impact model (BIM) was developed and populated from the perspective of Argentinean payers over a three-year time horizon. Eligible patients were over 40 years old (INDEC 2023). Epidemiology assumptions such as prevalence (14.5%), moderate to severe COPD (61%) and patient eligibility for triple therapy were obtained from a local study and validated by medical experts. Around 213,510 patients were estimated and included in the BIM. The acquisition cost of therapies was obtained from public data sources (Kairos). Moderate and severe exacerbation costs were estimated based on previous published work in Argentina. All costs were expressed in USD on 15 Jun 2023 (1 USD = 258 ARG). This base case assumes that adopting multiple inhaler triple therapies (MITTs) is reduced and moved from 50%/40%/35% to 40%/30%/25% in terms of usage over three-year horizon
RESULTS: Over three years, adopting SITT generated savings accumulating to US$10.78m. Savings were primarily driven by lower treatment acquisition costs vs. MITT (US$9.1). Rescue therapies and moderate exacerbation savings were USD 0.4 m and USD 1.1 m, respectively
CONCLUSIONS: Single Inhaler Triple Therapy (SITT: ICS/LAMA/LABA) offers cost-savings to a healthcare budget when replacing multiple inhaler triple therapies (MITTs) in Argentina for patients with moderate to very severe COPD
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE95
Topic
Economic Evaluation, Health Technology Assessment
Topic Subcategory
Budget Impact Analysis
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)